drugset / Trial / NCT05946122
Effect of Atorvastatin as a Renal Protection in Patients With Systemic Inflammatory Response Syndrome Using Renal Arterial Resistive Index
RandomizedParallel-groupDouble-blindPrevention
Summary
Offering renal protection in systemic inflammatory response syndrome by atorvastatin
Timeline
- Start
- 2023-05-30
- Primary completion
- 2023-12-12
- Completion
- 2023-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atorvastatin | Small molecule | 40 mg | Oral |
Indications
No indication recorded.